JP2011525191A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011525191A5 JP2011525191A5 JP2011514851A JP2011514851A JP2011525191A5 JP 2011525191 A5 JP2011525191 A5 JP 2011525191A5 JP 2011514851 A JP2011514851 A JP 2011514851A JP 2011514851 A JP2011514851 A JP 2011514851A JP 2011525191 A5 JP2011525191 A5 JP 2011525191A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable composition
- antigen
- cells
- csf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cells Anatomy 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 102000038129 antigens Human genes 0.000 claims 4
- 108091007172 antigens Proteins 0.000 claims 4
- 230000000240 adjuvant Effects 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 210000000612 Antigen-Presenting Cells Anatomy 0.000 claims 2
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 2
- 102100006400 CSF2 Human genes 0.000 claims 1
- 241000186216 Corynebacterium Species 0.000 claims 1
- 241001464975 Cutibacterium granulosum Species 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 108010074108 interleukin-21 Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 230000001235 sensitizing Effects 0.000 claims 1
- 231100000202 sensitizing Toxicity 0.000 claims 1
Claims (4)
- 最低１種のＣＭＶ抗原若しくは該最低１種のＣＭＶ抗原をコードする核酸、または
抗原提示細胞およびＴリンパ球が感作有効量の最低１種のＣＭＶ抗原でｉｎ ｖｉｔｒｏで感作されている、有効量の該抗原提示細胞、該Ｔリンパ球若しくは双方、
を含んでなる製薬学的に許容できる組成物であって、該製薬学的に許容できる組成物が、ＣＭＶ抗原を発現する細胞に対する免疫応答を誘発するためのものであり、該細胞が、前癌細胞、癌細胞、若しくはＣＭＶと関連する癌を発症させる細胞型を特徴とする、上記組成物。 - アジュバントをさらに含んでなる、請求項１に記載の製薬学的に許容できる組成物。
- アジュバントが、ＧＭ−ＣＳＦ、Ｇ−ＣＳＦ、ＩＬ−２、ＩＬ−４、ＩＬ−７、ＩＬ−１２、ＩＬ−１５、ＩＬ−２１、ＴＮＦ−α、Ｍ−ＣＳＦ、フロイントの不完全アジュバント（モンタニドＩＳＡ ５１）およびコリネバクテリウム グラヌロサム（Ｃｏｒｙｎｅｂａｃｔｅｒｉｕｍ ｇｒａｎｕｌｏｓｕｍ）Ｐ４０よりなる群から選択される、請求項２に記載の製薬学的に許容できる組成物。
- 被験体における癌の処置若しくは重症度の低下における使用のための、予防的若しくは治療的有効量の請求項１−３のいずれか１つに記載の製薬学的に許容できる組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7458208P | 2008-06-20 | 2008-06-20 | |
| US61/074,582 | 2008-06-20 | ||
| PCT/US2009/047987 WO2009155535A2 (en) | 2008-06-20 | 2009-06-19 | Compositions, methods and kits for eliciting an immune response |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015016782A Division JP2015134767A (ja) | 2008-06-20 | 2015-01-30 | 免疫応答を誘発するための組成物、方法およびキット |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011525191A JP2011525191A (ja) | 2011-09-15 |
| JP2011525191A5 true JP2011525191A5 (ja) | 2012-08-09 |
Family
ID=41434717
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011514851A Pending JP2011525191A (ja) | 2008-06-20 | 2009-06-19 | 免疫応答を誘発するための組成物、方法およびキット |
| JP2015016782A Pending JP2015134767A (ja) | 2008-06-20 | 2015-01-30 | 免疫応答を誘発するための組成物、方法およびキット |
| JP2016249706A Active JP6342982B2 (ja) | 2008-06-20 | 2016-12-22 | 免疫応答を誘発するための組成物、方法およびキット |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015016782A Pending JP2015134767A (ja) | 2008-06-20 | 2015-01-30 | 免疫応答を誘発するための組成物、方法およびキット |
| JP2016249706A Active JP6342982B2 (ja) | 2008-06-20 | 2016-12-22 | 免疫応答を誘発するための組成物、方法およびキット |
Country Status (8)
| Country | Link |
|---|---|
| US (12) | US8425898B2 (ja) |
| EP (4) | EP3766517B1 (ja) |
| JP (3) | JP2011525191A (ja) |
| CN (1) | CN102123732A (ja) |
| AU (1) | AU2009259923B2 (ja) |
| CA (1) | CA2728739C (ja) |
| DK (1) | DK3156069T3 (ja) |
| WO (1) | WO2009155535A2 (ja) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008116468A2 (en) | 2007-03-26 | 2008-10-02 | Dako Denmark A/S | Mhc peptide complexes and uses thereof in infectious diseases |
| EP3023436A1 (en) | 2007-07-03 | 2016-05-25 | Dako Denmark A/S | Improved methods for generation, labeling and use of mhc multimers |
| EP2197908A2 (en) | 2007-09-27 | 2010-06-23 | Dako Denmark A/S | Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics |
| US10968269B1 (en) | 2008-02-28 | 2021-04-06 | Agilent Technologies, Inc. | MHC multimers in borrelia diagnostics and disease |
| EP3766517B1 (en) * | 2008-06-20 | 2022-11-02 | Duke University | Compositions, methods, and kits for eliciting an immune response |
| WO2010009735A2 (en) | 2008-07-23 | 2010-01-28 | Dako Denmark A/S | Combinatorial analysis and repair |
| GB0817244D0 (en) | 2008-09-20 | 2008-10-29 | Univ Cardiff | Use of a protein kinase inhibitor to detect immune cells, such as T cells |
| US11992518B2 (en) | 2008-10-02 | 2024-05-28 | Agilent Technologies, Inc. | Molecular vaccines for infectious disease |
| US10369204B2 (en) | 2008-10-02 | 2019-08-06 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| WO2011127129A1 (en) * | 2010-04-06 | 2011-10-13 | Holaday John W | Methods of treating cancer |
| WO2012141653A1 (en) | 2011-04-15 | 2012-10-18 | Naucler Cecilia | Genetic variant of cytomegalovirus (cmv) |
| CN102363818B (zh) * | 2011-06-28 | 2013-01-02 | 同昕生物技术（北京）有限公司 | 同时检测人ebv、bkv和 cmv的三重实时荧光定量pcr方法及试剂盒 |
| SG11201501623PA (en) * | 2012-10-30 | 2015-05-28 | Redvax Gmbh | Recombinant particle based vaccines against human cytomegalovirus infection |
| EP2956557B1 (en) * | 2013-02-14 | 2018-07-11 | The J. David Gladstone Institutes | Compositions and methods of use thereof for identifying anti-viral agents |
| WO2015047901A1 (en) * | 2013-09-24 | 2015-04-02 | Duke University | Compositions, methods and kits for eliciting an immune response |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| WO2015073801A1 (en) | 2013-11-14 | 2015-05-21 | Duke University | Tetanus toxoid and ccl3 improve dc vaccines |
| EP3074770B1 (en) | 2013-11-26 | 2020-04-29 | Duke University | Immune monitoring to predict and prevent infection |
| MX2017005707A (es) | 2014-11-05 | 2017-08-21 | Memorial Sloan Kettering Cancer Center | Metodos para seleccionar una linea de celulas t y el donador de la misma para terapia celular adoptiva. |
| US20180133327A1 (en) | 2015-03-16 | 2018-05-17 | Amal Therapeutics Sa | Cell Penetrating Peptides and Complexes Comprising the Same |
| EP4306955A3 (en) * | 2015-03-26 | 2024-03-06 | University of Houston System | Integrated functional and molecular profiling of cells |
| EP3313419B1 (en) | 2015-06-26 | 2020-08-19 | Memorial Sloan Kettering Cancer Center | Methods of treating cmv retinitis by t cell therapy |
| AU2016342045A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| WO2017096247A1 (en) * | 2015-12-04 | 2017-06-08 | Mayo Foundation For Medical Education And Research | Methods and vaccines for inducing immune responses to multiple different mhc molecules |
| JP2019502725A (ja) | 2016-01-20 | 2019-01-31 | フェイト セラピューティクス，インコーポレイテッド | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| CA3031170A1 (en) | 2016-09-21 | 2018-03-29 | Amal Therapeutics Sa | Fusion comprising a cell penetrating peptide, a multi epitope and a tlr peptide agonist for treatment of cancer |
| US10857182B2 (en) | 2016-09-23 | 2020-12-08 | Memorial Sloan Kettering Cancer Center | Generation and use in adoptive immunotherapy of stem cell-like memory T cells |
| JP6980780B2 (ja) * | 2016-10-21 | 2021-12-15 | モデルナティーエックス， インコーポレイテッド | ヒトサイトメガロウイルスワクチン |
| WO2018106595A1 (en) | 2016-12-05 | 2018-06-14 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| WO2019083866A1 (en) | 2017-10-23 | 2019-05-02 | Atara Biotherapeutics, Inc. | METHODS FOR ADJUSTING IMMUNOTHERAPY MANAGEMENT TUMORAL FLOOD MANAGEMENT |
| WO2019090304A1 (en) * | 2017-11-06 | 2019-05-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cancer treatment utilizing pre-existing microbial immunity |
| CN111918666A (zh) | 2018-02-02 | 2020-11-10 | Sl瓦西基因公司 | 一种新型疫苗佐剂 |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| CA3142110A1 (en) * | 2019-05-31 | 2020-12-03 | Variation Biotechnologies Inc. | Immunotherapeutic compositions for treatment of glioblastoma multiforme |
| JP2022547298A (ja) * | 2019-09-09 | 2022-11-11 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫療法組成物 |
| JP2023078487A (ja) * | 2020-04-08 | 2023-06-07 | アステラス製薬株式会社 | がんの処置に用いるｐｐ６５含有人工アジュバントベクター細胞 |
| US11857622B2 (en) | 2020-06-21 | 2024-01-02 | Pfizer Inc. | Human cytomegalovirus GB polypeptide |
| EP4192494A1 (en) * | 2020-08-06 | 2023-06-14 | La Jolla Institute for Immunology | Methods for treating and preventing cytomegalovirus infection |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| GB2603166A (en) * | 2021-01-29 | 2022-08-03 | Thelper As | Therapeutic and Diagnostic Agents and Uses Thereof |
| WO2022192323A1 (en) * | 2021-03-09 | 2022-09-15 | Board Of Regents, The University Of Texas System | Low intensity ultrasound combination cancer therapies |
| CN117257925B (zh) * | 2023-09-20 | 2024-05-28 | 青岛大学 | 基于人巨细胞病毒编码即刻早期蛋白ie的疫苗、其制备方法和应用 |
| CN117169518B (zh) * | 2023-11-03 | 2024-01-19 | 赛德特(北京)生物工程有限公司 | T淋巴细胞制剂中的cd3抗体残留物的检测方法和试剂盒 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| US6207161B1 (en) | 1986-07-16 | 2001-03-27 | City Of Hope | Induction of cytolytic T-lymphocytes with cytomegalovirus polypeptides |
| US4906564A (en) | 1987-03-13 | 1990-03-06 | The United States Of America As Represented By The Secretary Of The Army | Antigenic determinants recognized by antibodies obtained using a pathogenic agent or a derivative thereof that presents a restricted set of antigens |
| DE69132311T2 (de) | 1990-09-25 | 2000-12-14 | Cantab Pharma Res | Bei einer transkomplementenden zellinie erzeugter defektiver virenimpfstoff |
| EP0683675A4 (en) * | 1993-01-28 | 1997-05-21 | Sandoz Pharmaceuticals Corp | HUMAN MONOCLONAL ANTIBODIES AGAINST CYTOMEGALOVIRUS. |
| JPH08507784A (ja) | 1993-03-19 | 1996-08-20 | キャンタブ ファーマシューティカルズ リサーチ リミティド | ウイルス・ワクチン |
| AU2809897A (en) | 1996-04-23 | 1997-11-12 | Wistar Institute Of Anatomy And Biology, The | Novel human cytomegalovirus dna constructs and uses therefor |
| US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| US6562345B1 (en) * | 1996-11-12 | 2003-05-13 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
| US6156317A (en) * | 1996-11-12 | 2000-12-05 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
| US6074645A (en) * | 1996-11-12 | 2000-06-13 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
| US6503503B1 (en) | 1997-05-13 | 2003-01-07 | Duke University | Allogeneic cellular vaccine |
| US6013258A (en) | 1997-10-09 | 2000-01-11 | Zycos Inc. | Immunogenic peptides from the HPV E7 protein |
| US6291446B1 (en) | 1998-03-05 | 2001-09-18 | Eli Lilly And Company | Therapeutic treatment for cytomegalovirus infection |
| IL125608A0 (en) | 1998-07-30 | 1999-03-12 | Yeda Res & Dev | Tumor associated antigen peptides and use of same as anti-tumor vaccines |
| CA2341361A1 (en) | 1998-08-31 | 2000-03-09 | Oregon Health Sciences University | Prevention of cell migration initiation with cmv us28 receptor antagonists |
| US6572856B1 (en) | 1998-09-10 | 2003-06-03 | The University Of Virginia Patent Foundation | Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies |
| US6350451B1 (en) | 1999-06-25 | 2002-02-26 | The Board Of Trustees Of The University Of Arkansas | Immunotherapy of epithelial tumors using intralesional injection of antigens that induce a delayed type hypersensitivity reaction |
| US7005131B1 (en) | 1999-08-13 | 2006-02-28 | The Rockefeller University | Protective antigen of Epstein Barr Virus |
| AU2001240109A1 (en) | 2000-03-07 | 2001-09-17 | U.S. Army Medical Research Institute Of Infectious Diseases | Dna vaccines against poxviruses |
| CA2403681A1 (en) | 2000-03-21 | 2001-09-27 | Genzyme Corporation | Therapeutic anti-cytomegalovirus compounds |
| EP1146119A1 (en) | 2000-04-12 | 2001-10-17 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for obtaining specific T-lymphocytes, and for identifying unknown epitopes |
| AU2001288682A1 (en) * | 2000-08-30 | 2002-03-13 | Chemocentryx, Inc. | Inhibition of cmv infection and dissemination |
| CA2427257C (en) | 2000-11-01 | 2014-01-21 | The Government Of The United States Of America | Expression vectors able to elicit improved immune response and methods of using same |
| WO2002062296A2 (en) | 2001-02-02 | 2002-08-15 | Chemocentryx, Inc. | Methods and compositions useful for stimulating an immune response |
| AUPR395801A0 (en) | 2001-03-26 | 2001-04-26 | Austin Research Institute, The | Antibodies against cancer |
| AUPR593101A0 (en) * | 2001-06-26 | 2001-07-19 | Council Of The Queensland Institute Of Medical Research, The | Cytomegalovirus t cell epitopes |
| AU2003268355A1 (en) | 2002-09-03 | 2004-03-29 | The Uab Research Foundation | Localization of human cytomegalovirus nucleic acids and proteins in human cancer cells |
| US7740871B2 (en) | 2002-09-19 | 2010-06-22 | Johns Hopkins University School Of Medicine | Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine |
| DK1408106T3 (da) | 2002-10-11 | 2007-06-11 | Sentoclone Ab | Cancer immunterapi |
| AU2003296439B2 (en) | 2002-12-10 | 2009-05-07 | Argos Therapeutics, Inc. | In situ maturation of dendritic cells |
| US7410795B2 (en) | 2002-12-23 | 2008-08-12 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
| WO2004093905A1 (en) * | 2003-04-16 | 2004-11-04 | City Of Hope | Human cytomegalovirus antigens expressed in mva and methods of use |
| US20050232933A1 (en) * | 2003-09-30 | 2005-10-20 | Zaia John A | CMV-IE1 peptides and method of use |
| WO2006056027A1 (en) | 2004-11-29 | 2006-06-01 | The Council Of The Queensland Institute Of Medical Research | Human cytomegalovirus immunotherapy |
| WO2007130470A2 (en) * | 2006-05-01 | 2007-11-15 | The Regents Of The University Of California | Cytomegalovirus peptides and methods of use thereof |
| WO2008039969A2 (en) | 2006-09-28 | 2008-04-03 | Cedars-Sinai Medical Center | Cancer vaccines and vaccination methods |
| WO2009021150A2 (en) * | 2007-08-08 | 2009-02-12 | California Pacific Medical Center | Platelet derived growth factor receptor supports cytomegalovirus infectivity |
| EP3766517B1 (en) * | 2008-06-20 | 2022-11-02 | Duke University | Compositions, methods, and kits for eliciting an immune response |
| WO2010002983A2 (en) | 2008-07-03 | 2010-01-07 | Duke University | Composition and methods for eliciting an immune response |
| WO2015073801A1 (en) * | 2013-11-14 | 2015-05-21 | Duke University | Tetanus toxoid and ccl3 improve dc vaccines |
-
2009
- 2009-06-19 EP EP20181935.6A patent/EP3766517B1/en active Active
- 2009-06-19 CN CN2009801288723A patent/CN102123732A/zh active Pending
- 2009-06-19 CA CA2728739A patent/CA2728739C/en active Active
- 2009-06-19 EP EP16184921.1A patent/EP3156069B8/en active Active
- 2009-06-19 AU AU2009259923A patent/AU2009259923B2/en active Active
- 2009-06-19 EP EP09767844.5A patent/EP2303319B1/en active Active
- 2009-06-19 JP JP2011514851A patent/JP2011525191A/ja active Pending
- 2009-06-19 EP EP22202748.4A patent/EP4218806A1/en active Pending
- 2009-06-19 US US12/488,176 patent/US8425898B2/en active Active
- 2009-06-19 DK DK16184921.1T patent/DK3156069T3/da active
- 2009-06-19 WO PCT/US2009/047987 patent/WO2009155535A2/en active Application Filing
-
2013
- 2013-01-23 US US13/748,096 patent/US9011835B2/en active Active
-
2015
- 2015-01-30 JP JP2015016782A patent/JP2015134767A/ja active Pending
- 2015-04-08 US US14/681,534 patent/US9764026B2/en active Active
-
2016
- 2016-12-22 JP JP2016249706A patent/JP6342982B2/ja active Active
-
2017
- 2017-08-14 US US15/676,330 patent/US10632190B2/en not_active Expired - Fee Related
-
2020
- 2020-03-18 US US16/822,354 patent/US11389530B2/en active Active
- 2020-07-22 US US16/935,813 patent/US11351248B2/en active Active
- 2020-07-23 US US16/937,171 patent/US11364295B2/en active Active
- 2020-07-24 US US16/937,801 patent/US11376322B2/en active Active
-
2022
- 2022-05-06 US US17/738,576 patent/US20220370602A1/en not_active Abandoned
- 2022-05-17 US US17/746,329 patent/US20220387582A1/en not_active Abandoned
- 2022-05-31 US US17/828,554 patent/US20220378906A1/en active Pending
- 2022-06-15 US US17/841,140 patent/US20220401552A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011525191A5 (ja) | ||
| JP2023052777A5 (ja) | ||
| JP2011188872A5 (ja) | ||
| Durward et al. | Active evasion of CTL mediated killing and low quality responding CD8+ T cells contribute to persistence of brucellosis | |
| JP2013504623A5 (ja) | ||
| EP2385059A3 (en) | Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma | |
| JP2012526853A5 (ja) | ||
| JP2020516658A5 (ja) | ||
| JP2013512694A5 (ja) | ||
| WO2009089535A3 (en) | Polypeptide vaccine and vaccination strategy against mycobacterium | |
| WO2006047515A3 (en) | Dendritic cells loaded with heat shocked melanoma cell bodies | |
| JP2014507482A5 (ja) | ||
| WO2006041933A3 (en) | Improved vaccines | |
| DK2102331T3 (da) | Anti-tumorvaccine afledt af normale kemisk modificerede CD4 -celler | |
| JP2016513115A5 (ja) | ||
| RU2015117251A (ru) | Новые соединения | |
| WO2009114085A3 (en) | Allogeneic cancer cell-based immunotherapy | |
| RU2015101110A (ru) | Вакцинные композиции с катионными липидами и способы применения | |
| JP2013545448A5 (ja) | ||
| JP2018501322A5 (ja) | ||
| Singh et al. | Manipulation of BCG vaccine: a double-edged sword | |
| Wei et al. | Kinetics of Th 17‐related cytokine expression in experimentally induced rat periapical lesions | |
| JP2013507945A5 (ja) | ||
| JP2015526469A5 (ja) | ||
| JP2014533938A5 (ja) |